Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Testicular Cancer Clinical Trial

Official title:

Phase II Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02860819
• Other study ID #: GCTSK004
• Status: Completed
• Phase: Phase 2
• Start date: August 1, 2016
• Est. completion date: February 15, 2021

Study information

• Verified date: December 2020
• Source: National Cancer Institute, Slovakia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a proof-of-concept study to define efficacy of gemcitabine, carboplatin and VELIPARIB (ABT-888) in patients with refractory germ cell tumors (GCTs). PARP proteins are involved in base excision repair (BER), one of the major DNA repair system in cells and PARP is overexpressed in testicular GCTs (TGCTs) compared to normal testis and data suggest that PARP overexpression is early event in TGCTs development. Patients with low PARP expression in primary tumour had non-significantly better OS compared to patients with high PARP expression (5-year OS 89.2% vs 78.7%; HR=0.50, 95% CI 0.21 to 1.17, p=0.12). The aim of this study is to evaluate PARP inhibitor VELIPARIB in combination with gemcitabine, carboplatin in patients with refractory germ cell tumors (GCTs).

Description:

PARP proteins are involved in base excision repair (BER), one of the major DNA repair system in cells. Recently, it was showed that PARP inhibitors have striking efficacy in patients with BRCA1 deficient or triple negative breast cancer in monotherapy or in combination with cisplatin based chemotherapy, without increased systemic toxicity. Pertubations affecting homologous recombination (HR) involved in DNA repair are associated with higher probability of response to PARP inhibitors. Inactivation of PTEN, tumor suppressor protein, is associated with defects in HR and response to PARP inhibitors.

Recently, PARP expression was evaluated in TGCTs. It was showed that PARP is overexpressed in testicular germ cell tumours compared to normal testis and PARP overexpression is early event in TGCTs development. Patients with low PARP expression in primary tumour had non-significantly better OS compared to patients with high PARP expression (5-year OS 89.2% vs 78.7%; HR=0.50, 95% CI 0.21 to 1.17, p=0.12).Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. In the testis, PTEN was abundantly expressed in germ cells whereas it was virtually absent from 56% of seminomas as well as from 86% of embryonal carcinomas and virtually all teratomas. On the contrary, ITGCN intensely expressed PTEN, indicating that loss of PTEN expression is not in early event in testicular tumor development, but is associated with progression of disease. Previously, it was showed, that testicular germ cell tumors cell lines have low activity of proteins involved in nuclear excision repair (NER) and it is assumed that low NER activity is related to the favorable response of testis tumors to cisplatin-based chemotherapy.

Gemcitabine and carboplatin showed activity in refractory TGCTs. Recently, maximal tolerated dose of Veliparib (ABT-888) with gemcitabine and carboplatin was established.

Based on aforementioned data, there is strong rationale to inhibit PARP in TGCT. Inactivation of PARP by Veliparib along with defects of homologous recombination due to PTEN inactivation in GCTs and low activity of nucleotide excision repair system will dramatically increase antitumor effect gemcitabine and carboplatin in patients with progressing or relapsing germ cell cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: February 15, 2021
• Est. primary completion date: November 30, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. Men aged 18 years or older

3. ECOG performance status: 0-1,

4. Histologically confirmed extracranial primary germ cell cancer, seminoma, or nonseminoma

5. Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin) on sequential measurement or biopsy-proven unresectable germ cell cancer

6. Refractory GCTs e.g. patients relapsing after high-dose chemotherapy or for patients non fit enough for high-dose chemotherapy

7. Primary mediastinal GCTs in first relapse

8. Patient's disease must not be amenable to cure with either surgery or chemotherapy in the opinion of investigator,

9. Measurable disease radiologically

10. Adequate hematologic function defined by ANC > 1500/mm3, platelet count > 100 000/mm3 and hemoglobin level > 9g/dl.

11. Adequate liver function defined by a total bilirubin level < 1.5 ULN, and ALT, AST < 3 ULN or < 5 in case of liver metastases. For subjects with Gilbert's syndrome bilirubin > 1.5 × ULN is allowed if no symptoms of compromised liver function are present

12. Adequate renal function: measured or calculated (by Cockcroft formula) creatinine clearance > 50 ml/min. Cockcroft formula: CLcr = [(140-age) x weight(Kg)]/[72 x creatinine (mg/dl)]

13. At least 4 weeks must have elapsed since the last radiotherapy and/or chemotherapy before study entry,

14. At least 4 weeks must have elapsed since the last major surgery

15. Complete recovery from prior surgery, and/or reduction of all adverse events from previous systemic therapy or radiotherapy to grade 1,

16. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Exclusion Criteria:

1. Patients who do not fit inclusion criteria

2. Other prior malignancy except successfully treated nonmelanoma skin cancer

3. Prior PARP1 inhibitor

4. Other concurrent approved or investigational anticancer treatment, including surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or immunotherapy

5. Female patients

6. Patients infected by the Human Immunodeficiency Virus (HIV)

7. Patients with other severe acute or chronic medical condition, or laboratory abnormality that would impair, in the judgment of investigator, excess risk associated with study treatment, or which, in judgment of the investigator, would make the patient inappropriate for entry into this study

8. Inability of oral intake, or drug absorption (e.g. malabsorption syndrome)

9. Hypersensitivity to any compound of the drug

10. Sexually active men not using highly effective birth control if their partners are women of child-bearing potential

11. Patients with history of or current CNS metastasis

12. Patients with history of seizures

Related Conditions & MeSH terms

• Neoplasms, Germ Cell and Embryonal
• Testicular Cancer
• Testicular Neoplasms

Intervention

Drug:
• Veliparib
Veliparib 250mg BID, continuously
• Gemcitabine
Gemcitabine 800mg/m2, day 1 and 8
• Carboplatin
Carboplatin AUC = 4, day 1

Locations

Country	Name	City	State
Slovakia	National Cancer Institute	Bratislava

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute, Slovakia

Country where clinical trial is conducted

Slovakia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients that will be free of disease progression according to RECIST criteria 12-months after the first administration of the treatment.	Percentage of patients that will be free of disease progression according to RECIST criteria 12-months after the first administration of the treatment.	12-months
Secondary	Response rate	Response rate as measured by RECIST 1.1	6-weeks
Secondary	Median overall survival	Median overall survival. Overall survival will be measured from the date of first administration of the treatment until death or date of last follow-up.	12 months
Secondary	Median progression-free survival	Median progression-free survival. Progression-free survival will be measured from the date of first administration of the treatment until progression, death or date of last follow-up.	12-months
Secondary	Frequency of grade III and IV adverse events	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	3-weeks